Tatsuo Kawai
Principal Investigator / Transplant Surgeon · Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tatsuo Kawai as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:34 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT06972069 · Tolerance Through Mixed Chimerism (Sip-Tego)Tatsuo Kawai, MD, PhD · active not recruiting · Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance · principal investigator
- Ph1/Ph2NCT05900401 · Delayed Tolerance Through Mixed ChimerismMassachusetts General Hospital · recruiting · Kidney Failure, Kidney Transplant; Complications, Chimera · principal investigator
- Ph1NCT02314403 · Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)Massachusetts General Hospital · completed · Kidney Failure, Chronic, Renal Insufficiency · principal investigator
- N/ANCT01021839 · Comparison of Bovine Carotid Artery and Expanded Polytetrafluoroethylene (ePTFE) for Permanent Hemodialysis AccessMassachusetts General Hospital · completed · Kidney Failure, Renal Dialysis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 1: Translating Renal XenotransplantationU19AI191384 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2025 to 2026 · $869,504 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting innate immunity for induction of robust renal allograft toleranceU01AI174968 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2023 to 2026 · $1,074,143 awarded in 2026Same name and institution; not confirmed by an ID
- Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primatesR01AI155714 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2022 to 2025 · $1,845,438 awarded in 2025Same name and institution; not confirmed by an ID
- Mcl-1 inhibition for induction of hematopoietic chimerism without nonselective myeloablative treatments in nonhuman primatesR21AI163806 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2021 to 2022 · $203,795 awarded in 2022Same name and institution; not confirmed by an ID
- Inhibition of Bcl-2 for Induction of Mixed Chimerism and Renal Allograft Tolerance Without MyelosuppressionR56AI139679 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2018 · $677,954 awarded in 2018Same name and institution; not confirmed by an ID
- Inhibition of BCL-2 for induction of mixed chimerism without myelosuppressive conditioningR21AI126289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2016 to 2017 · $210,200 awarded in 2017Same name and institution; not confirmed by an ID
- Tolerance of Kidney and Islet Transplants via the Mixed Chimerism ApproachU19AI102405 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2012 to 2016 · $573,942 awarded in 2016Same name and institution; not confirmed by an ID
- Optimizing Mixed-Chimerism for Heart Transplantation in Non-Human PrimatesR01HL093131 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2009 to 2010 · $752,796 awarded in 2010Same name and institution; not confirmed by an ID
- MIXED CHIMERISM AND TOLERANCE IN CYNOMOLGUS MONKEYSR01AI037692 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2004 to 2005 · $408,921 awarded in 2005Same name and institution; not confirmed by an ID
- MIXED CHIMERISM AND TOLERANCE IN CYNOMOLGUS MONKEYSR21AI037692 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2000 · $231,650 awarded in 2000Same name and institution; not confirmed by an ID
- XENOGENEIC ISLET CELL TRANSPLANTATIONF05TW004720 · FIC · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 1992 to 1993 · $36,100 awarded in 1993Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:34 UTC. The ranking covers the 200 most relevant of 106 PubMed records, and a shared surname and initials can bring in a namesake. All 106 on PubMed
- 100 citationsRCR 3.7
- Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.Gut · 201897 citationsRCR 5.0
- 83 citationsRCR 4.7
- Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.Metabolism · 199978 citationsRCR 1.8
- Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus.Diabetes · 199176 citationsRCR 2.8
- Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: a preliminary, single-center, randomized controlled trial.J Hepatobiliary Pancreat Surg · 200774 citationsRCR 3.0
- 70 citationsRCR 4.1
- Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities.J Gastroenterol Hepatol · 200863 citationsRCR 2.3
- 62 citationsRCR 3.1
- Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.Clin Rheumatol · 201260 citationsRCR 2.4